PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28755537-1 2017 OBJECTIVE: Data on the effect of gender on the interpretation of the GHRH plus arginine stimulation test (GHRH+ARG test) is controversial. Arginine 79-87 growth hormone releasing hormone Homo sapiens 106-110 28755537-11 2017 CONCLUSIONS: The GH response to stimulation by GHRH+ARG is gender-dependent, being lower in healthy males than in females. Arginine 52-55 growth hormone releasing hormone Homo sapiens 47-51 26874855-2 2016 We aimed to establish a cut-off value for the GHRH-arginine test (GHRH+ARG) at the typical age of retesting at near-adult height. Arginine 51-59 growth hormone releasing hormone Homo sapiens 46-50 26874855-2 2016 We aimed to establish a cut-off value for the GHRH-arginine test (GHRH+ARG) at the typical age of retesting at near-adult height. Arginine 51-59 growth hormone releasing hormone Homo sapiens 66-70 26874855-2 2016 We aimed to establish a cut-off value for the GHRH-arginine test (GHRH+ARG) at the typical age of retesting at near-adult height. Arginine 71-74 growth hormone releasing hormone Homo sapiens 46-50 24322605-7 2014 Additionally, in the chronic phase, GHRH-arginine test was used for the diagnosis of growth hormone (GH) deficiency. Arginine 41-49 growth hormone releasing hormone Homo sapiens 36-40 24096994-9 2014 After GHRH-ARG the mean GH peak levels (GH-P) and GH response (as Area Under Curve, GH-AUC) were lower in SH+ than in SH- patients (15.2 +- 8.1 vs 44.5 +- 30.9 mug/L, P = 0.004 and 1,418 +- 803 vs 4,028 +- 2,476 mug/L/120 min, P = 0.002, respectively), after adjusting for age and BMI. Arginine 11-14 growth hormone releasing hormone Homo sapiens 6-10 24178787-3 2014 DESIGN: A total of 39 obese men and women with reduced GH secretion as determined by GHRH-arginine stimulation tests underwent magnetic resonance spectroscopy as part of a 12-month, double-blind, randomized, placebo-controlled trial comparing tesamorelin vs placebo. Arginine 90-98 growth hormone releasing hormone Homo sapiens 85-89 21220433-10 2011 Over the years, the test of first choice shifted from ITT toward GHRH-arginine test. Arginine 70-78 growth hormone releasing hormone Homo sapiens 65-69 23445176-8 2013 The subset of 12 patients with ALMS tested for GHRH-arg showed a significantly shorter stature than age-matched controls (154 7 +- 10 6 cm vs 162 9 +- 4 8 cm, P = 0 009) and a mild increase in BMI (Kg/m(2) ) (27 8 +- 4 8 vs 24 1 +- 2 5, P = 0 007). Arginine 52-55 growth hormone releasing hormone Homo sapiens 47-51 23913118-4 2013 We analyzed the GH-IGF1 axis by GHRH-arginine test in 30 healthy adolescents with normal stature during the transition period from 14 to 18 years. Arginine 37-45 growth hormone releasing hormone Homo sapiens 32-36 22269954-5 2012 We separately studied four patients who were diagnosed with GHD according to the GHRH-arginine test. Arginine 86-94 growth hormone releasing hormone Homo sapiens 81-85 21307143-4 2011 METHODS: Peak GH after GHRH-Arg and IGF1. Arginine 28-31 growth hormone releasing hormone Homo sapiens 23-27 21706189-9 2012 Hormonal alterations were only slight and no signs of anterior hypopituitarism were found except for an insufficient growth hormone rise in two overweight patients in the GHRH-ARG-test. Arginine 176-179 growth hormone releasing hormone Homo sapiens 171-175 20644702-11 2010 Aside from the insulin tolerance test, the GHRH-arginine test has become well established. Arginine 48-56 growth hormone releasing hormone Homo sapiens 43-47 20484474-1 2010 CONTEXT: The GHRH plus arginine (GHRH+Arg) test is a promising alternative to the insulin tolerance test (ITT) for diagnosis of adult GH deficiency (AGHD). Arginine 23-31 growth hormone releasing hormone Homo sapiens 33-37 20484474-1 2010 CONTEXT: The GHRH plus arginine (GHRH+Arg) test is a promising alternative to the insulin tolerance test (ITT) for diagnosis of adult GH deficiency (AGHD). Arginine 38-41 growth hormone releasing hormone Homo sapiens 13-17 20484474-11 2010 The cutoff value leading to 95% specificity with the GHRH+Arg test was measured at about 3.67 microg/liter (sensitivity 79.0%). Arginine 58-61 growth hormone releasing hormone Homo sapiens 53-57 21117918-4 2011 MAIN OUTCOME MEASURES: The GHRH-arginine test established GHD. Arginine 32-40 growth hormone releasing hormone Homo sapiens 27-31 19459759-6 2009 More than 2 years later, a subgroup of patients was re-evaluated using dynamic testing with ACTH and GHRH-arginine tests. Arginine 106-114 growth hormone releasing hormone Homo sapiens 101-105 20164294-7 2010 MAIN OUTCOME MEASURES: We measured the GH response to GHRH-ARG in aromatase-deficient men (at baseline and during estrogen treatment) and in normal subjects. Arginine 59-62 growth hormone releasing hormone Homo sapiens 54-58 19773395-1 2009 OBJECTIVE: The objective of the study was to reevaluate the diagnostic accuracy of GH peak after GHRH plus arginine test (GHRH+ARG) according to patients" age, body mass index (BMI), and waist circumference to diagnose GH deficiency (GHD). Arginine 107-115 growth hormone releasing hormone Homo sapiens 122-126 18765508-12 2008 CONCLUSIONS: GH response to GHRH-arginine testing is reduced in both overweight and obese subjects and negatively associated with indices of central abdominal obesity including WC, trunk fat, and visceral adipose tissue. Arginine 33-41 growth hormone releasing hormone Homo sapiens 28-32 19366847-9 2009 Peak GH levels after GHRH-arginine stimulation levels were inversely associated with QoL-AGHDA scale scores (R = -0.53; P = 0.0005) and the Symptom Questionnaire Depression subscale scores (R = -0.35; P = 0.031) and positively associated with most SF-36 subscale scores. Arginine 26-34 growth hormone releasing hormone Homo sapiens 21-25 19267411-7 2009 The GHRH + arginine induced GH rise in patients with del15q11-q13 was significantly higher than subjects with UPD15 (GH peak 7.7 +/- 1.7 microg/L vs. 2.7 +/- 1.0 microg/L, P < 0.05; AUC 458.5 +/- 91.0 microg/L/hr vs. 134.4 +/- 46.0 microg/L/hr, P < 0.02). Arginine 11-19 growth hormone releasing hormone Homo sapiens 4-8 19435823-8 2009 A GHRH-arginine stimulation test was performed. Arginine 7-15 growth hormone releasing hormone Homo sapiens 2-6 19509104-1 2009 CONTEXT: The use of the combined GHRH and arginine (GHRH-ARG) test has gained increasing acceptance in the United States as a reliable alternative test to the insulin tolerance test (ITT) for diagnosing adult GH deficiency (GHD). Arginine 42-50 growth hormone releasing hormone Homo sapiens 52-56 19509104-3 2009 In this article, we review the existing published data and consensus guidelines and provide recommendations for alternative stimulation tests to the GHRH-ARG test. Arginine 154-157 growth hormone releasing hormone Homo sapiens 149-153 19509104-5 2009 EVIDENCE SYNTHESIS: Previous consensus guidelines and previous data assessing the reliability and discriminatory value of the GHRH-ARG, glucagon, ARG, and GH secretagogues on assessing GH reserve are discussed. Arginine 131-134 growth hormone releasing hormone Homo sapiens 126-130 17709895-4 2007 Using BMI-related cut-off limits for peak GH response in the GHRH-arginine test, 4/16 beta-thalassemia patients had peak GH lower than 11.5 microg/l, the cut-off limit suggested for lean subjects, and were diagnosed as GH deficient (GHD). Arginine 66-74 growth hormone releasing hormone Homo sapiens 61-65 18221393-6 2008 Serum IGF-1 levels and peak GH levels in the patients that passed the GHRH-arginine test were compared with 22 age- and BMI-matched healthy controls. Arginine 75-83 growth hormone releasing hormone Homo sapiens 70-74 18221393-8 2008 Peak GH levels in patients that passed the GHRH-arginine test were lower compared to healthy controls and 19 patients (50%) had at least one other pituitary hormone deficit. Arginine 48-56 growth hormone releasing hormone Homo sapiens 43-47 18221393-10 2008 CONCLUSIONS: Our data demonstrated that a substantial number of patients with nonsecreting pituitary microadenomas failed the GHRH-arginine test despite normal serum IGF-1 levels, and had at least one other pituitary hormone deficiency, suggesting that nonsecreting microadenomas may not be clinically harmless. Arginine 131-139 growth hormone releasing hormone Homo sapiens 126-130 18445664-0 2008 Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. Arginine 62-70 growth hormone releasing hormone Homo sapiens 29-61 18544645-3 2008 We hypothesized that low-peak GH on the GH-releasing hormone (GHRH)-arginine stimulation test and high cortisol in overweight adolescents would be associated with higher regional fat, insulin resistance, and lipids. Arginine 68-76 growth hormone releasing hormone Homo sapiens 40-60 18544645-3 2008 We hypothesized that low-peak GH on the GH-releasing hormone (GHRH)-arginine stimulation test and high cortisol in overweight adolescents would be associated with higher regional fat, insulin resistance, and lipids. Arginine 68-76 growth hormone releasing hormone Homo sapiens 62-66 18544645-6 2008 Log peak GH on the GHRH-arginine test was lower (P = 0.03) and log UFC was higher (P = 0.02) in overweight girls. Arginine 24-32 growth hormone releasing hormone Homo sapiens 19-23 18057376-1 2007 OBJECTIVE: To define the appropriate diagnostic cut-off limits for the GH response to GHRH+arginine (ARG) test and IGF-I levels, using receiver operating characteristics (ROC) curve analysis, in late adolescents and young adults. Arginine 101-104 growth hormone releasing hormone Homo sapiens 86-90 18001199-8 2007 GH response to GHRH + ARG (arginine) positively correlated with Functional Independence Measure (FIM D; r = 0.267, p < 0.02) and Level of Cognitive Functioning Scale (LCFS D; r = 0.287, p < 0.01) at discharge, and negatively with Disability Rating Score at discharge (DRS D; r = -0.324, p < 0.005). Arginine 27-35 growth hormone releasing hormone Homo sapiens 15-19 17993769-3 2007 GH secretion, evaluated by GHRH+arginine (ARG) test, has recently been reported to be impaired in most untreated ALS patients. Arginine 42-45 growth hormone releasing hormone Homo sapiens 27-31 17595244-6 2007 Resistance to GHRH was assessed by GH response to GHRH plus arginine. Arginine 60-68 growth hormone releasing hormone Homo sapiens 14-18 17192289-0 2007 Combining growth hormone releasing hormone-arginine and synacthen testing diminishes the cortisol response. Arginine 43-51 growth hormone releasing hormone Homo sapiens 10-42 17289417-8 2007 CONCLUSION: Our data shows that a subpopulation of FM patients with low serum IGF-I levels will fail the GHRH-arginine test. Arginine 110-118 growth hormone releasing hormone Homo sapiens 105-109 17289417-10 2007 Additionally, the increased GH response rates to GHRH-arginine stimulation in the majority of FM patients with low serum IGF-I levels further supports the hypothesis of a dysregulated GH/IGF-I axis in the pathophysiology of FM. Arginine 54-62 growth hormone releasing hormone Homo sapiens 49-53 16728545-14 2006 The ITT (or the GHRH-arginine test) is therefore reliable in establishing the diagnosis of GHD in patients treated for acromegaly by surgery and radiotherapy. Arginine 21-29 growth hormone releasing hormone Homo sapiens 16-20 17072234-8 2006 Responses to ACTH or GHRH-arginine tests may be normal for several years though an ACTH and/or GH deficiency has been demonstrated by an insulin tolerance test, which is considered as the gold standard. Arginine 26-34 growth hormone releasing hormone Homo sapiens 21-25 17289417-4 2007 DESIGN: We retrospectively reviewed the GHRH-arginine data of 77 FM patients with low serum IGF-I levels referred to our tertiary unit over a 4-year period. Arginine 45-53 growth hormone releasing hormone Homo sapiens 40-44 18174711-3 2007 The most frequently used is the insulin tolerance test (ITT), followed in order by the arginine stimulation test (AST), the glucagon stimulation test (GST) and the GH-releasing hormone + arginine (GHRH+arg) test. Arginine 187-195 growth hormone releasing hormone Homo sapiens 197-201 18174749-3 2007 The most frequently used is the insulin tolerance test (ITT), followed in order by the arginine stimulation test (AST), the glucagon stimulation test (GST) and the GH-releasing hormone+arginine (GHRH+arg) test. Arginine 185-193 growth hormone releasing hormone Homo sapiens 195-199 16990654-2 2006 The GHRH + arginine (GHRH + ARG) test has been recommended as a reliable alternative to the insulin-tolerance test (ITT) as a standard test with a cutoff level of 9 ng/ml. Arginine 11-19 growth hormone releasing hormone Homo sapiens 21-25 16990654-2 2006 The GHRH + arginine (GHRH + ARG) test has been recommended as a reliable alternative to the insulin-tolerance test (ITT) as a standard test with a cutoff level of 9 ng/ml. Arginine 28-31 growth hormone releasing hormone Homo sapiens 4-8 16840832-3 2006 The GHRH+arginine (GHRH+ARG) test is likely to be the overall test of choice in clinical practice to differentiate GH deficiency (GHD) patients. Arginine 9-17 growth hormone releasing hormone Homo sapiens 19-23 16840832-3 2006 The GHRH+arginine (GHRH+ARG) test is likely to be the overall test of choice in clinical practice to differentiate GH deficiency (GHD) patients. Arginine 24-27 growth hormone releasing hormone Homo sapiens 4-8 16774477-4 2006 GH-secretory capacity was assessed with a GHRH-arginine stimulation test and GHD and GHI were defined as peak GH<6 or <or=12 ng/mL (5th and 10th percentiles of healthy control subjects, respectively). Arginine 47-55 growth hormone releasing hormone Homo sapiens 42-46 15853837-4 2005 Recent studies suggest that the GH releasing hormone + arginine (GHRH + ARG) test can identify GHD in cranially irradiated patients at longer time intervals after radiation. Arginine 55-63 growth hormone releasing hormone Homo sapiens 65-69 16061832-3 2005 Aim of this study was to evaluate the diagnostic cut-off limits of peak GH response to the GHRH-ARG test in overweight and obese as well as in lean population. Arginine 96-99 growth hormone releasing hormone Homo sapiens 91-95 16061832-4 2005 DESIGN AND METHODS: The GH responses to the GHRH-ARG test were studied in 322 patients with organic hypothalamic-pituitary disease and in 318 control subjects. Arginine 49-52 growth hormone releasing hormone Homo sapiens 44-48 16061832-14 2005 CONCLUSIONS: In conclusion the GHRH-ARG test is a reliable tool for the diagnosis of adult GH deficiency in lean, overweight and obese patients, provided that specific BMI-related cut-off limits are assumed. Arginine 36-39 growth hormone releasing hormone Homo sapiens 31-35 16131575-1 2005 CONTEXT: The insulin tolerance test (ITT) is the current standard diagnostic test for the diagnosis of adult GH deficiency (GHD), but alternative tests, such as the GHRH-arginine test, have been proposed. Arginine 170-178 growth hormone releasing hormone Homo sapiens 165-169 16131575-2 2005 OBJECTIVE: We investigated the sensitivity and specificity of the GHRH-arginine test using ITT as the gold standard in diagnosing GHD in a group of young adults treated with cranial irradiation (CRT) for childhood acute lymphoblastic leukemia (ALL). Arginine 71-79 growth hormone releasing hormone Homo sapiens 66-70 16131575-7 2005 In contrast, a failed GH response to the GHRH-arginine test accurately reflects the presence of radiation-induced GHD, illustrated by a high positive predictive value (95% at 7.5 microg/liter). Arginine 46-54 growth hormone releasing hormone Homo sapiens 41-45 16131575-8 2005 Only age at CRT and body mass index remained significant predictors of the peak GH during the GHRH-arginine test. Arginine 99-107 growth hormone releasing hormone Homo sapiens 94-98 16131575-9 2005 Because a high proportion of GHD patients show a normal response to the GHRH-arginine test, it cannot be used reliably to exclude GHD in these patients. Arginine 77-85 growth hormone releasing hormone Homo sapiens 72-76 15952410-1 2005 To verify if the entity of the peak GH responses to the GHRH+arginine (ARG) test is able to show different degree forms of GH deficiency (GHD), we linked these responses with the number of other anterior pituitary deficits. Arginine 71-74 growth hormone releasing hormone Homo sapiens 56-60 11834428-4 2002 RESULTS: The combined administration of GHRH-Ant distinctly inhibited the arginine- and insulin-induced GH release. Arginine 74-82 growth hormone releasing hormone Homo sapiens 40-44 12153607-12 2002 The GH response to GHRH was inhibited by OGTT (450.7 +/- 81.1 micro g/l/h, P < 0.05) and almost abolished by Li-He (230.0 +/- 63.6 micro g/l/h, P < 0.05) while was markedly potentiated by ARG (2520.4 +/- 425.8 micro g/l/h, P < 0.05). Arginine 194-197 growth hormone releasing hormone Homo sapiens 19-23 14616884-8 2003 Mean serum GH secretory peak after GHRH-Arg stimulation test was reduced in five subjects (mean 9.3 +/- 3.6 microg/l, P < 0.006 vs. Controls, mean 67.0 +/- 44.0 microg/l, cut-off, 16.0 microg/l) and normal in one subject (38.7 microg/l). Arginine 40-43 growth hormone releasing hormone Homo sapiens 35-39 12864804-7 2003 The relationship between the increment in serum GH following GHRH + GHRP-6 and arginine + GHRH test was positive, i.e. r = 0.749, P = 0.001.Thus, there was high concordance between both tests. Arginine 79-87 growth hormone releasing hormone Homo sapiens 61-65 12864804-7 2003 The relationship between the increment in serum GH following GHRH + GHRP-6 and arginine + GHRH test was positive, i.e. r = 0.749, P = 0.001.Thus, there was high concordance between both tests. Arginine 79-87 growth hormone releasing hormone Homo sapiens 90-94 11834428-0 2002 The role of endogenous GHRH in arginine-, insulin-, clonidine- and l-dopa-induced GH release in normal subjects. Arginine 31-39 growth hormone releasing hormone Homo sapiens 23-27 11834428-1 2002 OBJECTIVE: The role of endogenous GHRH in arginine-, insulin-, clonidine- and l-dopa-induced GH secretion was studied in man using a GHRH antagonist (GHRH-Ant). Arginine 42-50 growth hormone releasing hormone Homo sapiens 34-38 11834428-6 2002 These responses to arginine and insulin were also completely inhibited by the combined administration of GHRH-Ant. Arginine 19-27 growth hormone releasing hormone Homo sapiens 105-109 11061509-0 2000 Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans. Arginine 0-8 growth hormone releasing hormone Homo sapiens 130-162 11004017-6 2000 We infer from the present data that 1) exercise is likely to induce release of both GHRH and somatostatin, 2) L-arginine may facilitate the effect of exercise by limiting somatostatin release, 3) GHRP-2 could further enhance the stimulatory impact of exercise by opposing central actions of somatostatin and/or heightening endogenous GHRH release, and 4) gender strongly controls the relative but not absolute magnitude of A/G synergy both at rest and after exercise. Arginine 110-120 growth hormone releasing hormone Homo sapiens 334-338 11061526-3 2000 GHRH + arginine (GHRH+ARG) is the most reliable alternative to the insulin-induced hypoglycemia test (ITT) as a provocative test for the diagnosis of GHD in adulthood, provided that appropriate cut-off limits are assumed (normal limits, 16.5 microg/L as 3rd and 9.0 microg/L as 1st centile). Arginine 7-15 growth hormone releasing hormone Homo sapiens 17-21 11061526-3 2000 GHRH + arginine (GHRH+ARG) is the most reliable alternative to the insulin-induced hypoglycemia test (ITT) as a provocative test for the diagnosis of GHD in adulthood, provided that appropriate cut-off limits are assumed (normal limits, 16.5 microg/L as 3rd and 9.0 microg/L as 1st centile). Arginine 22-25 growth hormone releasing hormone Homo sapiens 0-4 11895217-10 2001 The blunting effect of digoxin on the GHRH-induced GH response is counteracted by arginine. Arginine 82-90 growth hormone releasing hormone Homo sapiens 38-42 11061509-10 2000 In conclusion, ARG counteracts the inhibitory effect of rhIGF-I on somatotroph responsiveness to GHRH in humans. Arginine 15-18 growth hormone releasing hormone Homo sapiens 97-101 10800760-11 2000 In obese PWS as well as in OB the GH response to GHRH+ARG was higher than that to GHRH+PD (p<0.02) which, in turn, was higher than that to CLO (p<0.001); all GH responses in obese PWS and OB were lower than those in NC (p<0.001) but similar to those in normal weight PWS. Arginine 54-57 growth hormone releasing hormone Homo sapiens 49-53 10718826-4 2000 GHRH + arginine test is more potent than the classical tests and evaluates the maximal secretory capacity of somatotroph cells. Arginine 7-15 growth hormone releasing hormone Homo sapiens 0-4 10718826-10 2000 On the other hand, the mean peak GH response to GHRH + ARG in GHNSD (43.7 +/- 3.7 micrograms/l) was markedly higher (P < 0.001) than that in GHD (8.2 +/- 0.9 micrograms/l) but significantly lower (P < 0.01) than that in NC (60. Arginine 55-58 growth hormone releasing hormone Homo sapiens 48-52 10800762-3 2000 ARG is also able to potentiate the GH response to GHRH, likely inhibiting hypothalamic somatostatin; this combined test is one of the most potent to explore the maximal secretory capacity of somatotroph cells. Arginine 0-3 growth hormone releasing hormone Homo sapiens 50-54 10800762-10 2000 The GH peak following ARG+GHRH (mean peak: 47.8+/-3.3 microg/l, p<0.001; Cmax 22.4-150.0 microg/l) was clearly higher (p<0.001) than that recorded after ARG alone. Arginine 159-162 growth hormone releasing hormone Homo sapiens 26-30 10800762-14 2000 ARG+GHRH is a more potent stimulus giving no false positive responses even after previous challenge with ARG alone. Arginine 105-108 growth hormone releasing hormone Homo sapiens 4-8 11202226-7 2000 Arginine potentiates both spontaneous and GHRH-induced GH secretion to the same extent in normally growing children, adults and elderly individuals, indicating that the releasable pool of GH is generally preserved across the human life span. Arginine 0-8 growth hormone releasing hormone Homo sapiens 42-46 10720081-17 2000 In summary, the present data suggest that in patients with incidental adrenal adenomas the GH response to GHRH is blunted due to increased somatostatinergic tone, as it can be restored to normal by pretreatment with the functional somatostatin antagonist arginine. Arginine 255-263 growth hormone releasing hormone Homo sapiens 106-110 10401710-15 1999 ; 2) HEX did not show more specificity than GHRH+PD and ARG+EE; 3) the association of GHRH+PD with ARG+EE could yield the best results at lower costs, confirming these tests as first-line tools in evaluating GH secretion. Arginine 99-102 growth hormone releasing hormone Homo sapiens 86-90 10664524-4 2000 On the other hand, it is well known that the GH response to GHRH in humans is markedly potentiated by arginine (ARG), which probably acts via inhibition of hypothalamic somatostatin release; in fact the GHRH+ARG test is known as one of the most reliable to evaluate the maximal secretory capacity of somatotroph cells. Arginine 102-110 growth hormone releasing hormone Homo sapiens 60-64 10664524-4 2000 On the other hand, it is well known that the GH response to GHRH in humans is markedly potentiated by arginine (ARG), which probably acts via inhibition of hypothalamic somatostatin release; in fact the GHRH+ARG test is known as one of the most reliable to evaluate the maximal secretory capacity of somatotroph cells. Arginine 102-110 growth hormone releasing hormone Homo sapiens 203-207 10664524-4 2000 On the other hand, it is well known that the GH response to GHRH in humans is markedly potentiated by arginine (ARG), which probably acts via inhibition of hypothalamic somatostatin release; in fact the GHRH+ARG test is known as one of the most reliable to evaluate the maximal secretory capacity of somatotroph cells. Arginine 112-115 growth hormone releasing hormone Homo sapiens 60-64 10664524-4 2000 On the other hand, it is well known that the GH response to GHRH in humans is markedly potentiated by arginine (ARG), which probably acts via inhibition of hypothalamic somatostatin release; in fact the GHRH+ARG test is known as one of the most reliable to evaluate the maximal secretory capacity of somatotroph cells. Arginine 112-115 growth hormone releasing hormone Homo sapiens 203-207 10664524-4 2000 On the other hand, it is well known that the GH response to GHRH in humans is markedly potentiated by arginine (ARG), which probably acts via inhibition of hypothalamic somatostatin release; in fact the GHRH+ARG test is known as one of the most reliable to evaluate the maximal secretory capacity of somatotroph cells. Arginine 208-211 growth hormone releasing hormone Homo sapiens 60-64 10664524-4 2000 On the other hand, it is well known that the GH response to GHRH in humans is markedly potentiated by arginine (ARG), which probably acts via inhibition of hypothalamic somatostatin release; in fact the GHRH+ARG test is known as one of the most reliable to evaluate the maximal secretory capacity of somatotroph cells. Arginine 208-211 growth hormone releasing hormone Homo sapiens 203-207 10443652-3 1999 GHRH plus arginine (ARG) is a more provocative test and is as sensitive as ITT provided that appropriate cut-off limits are assumed. Arginine 20-23 growth hormone releasing hormone Homo sapiens 0-4 9589665-3 1998 GHRH + arginine (GHRH + ARG) is one of the most promising tests in alternative to ITT. Arginine 7-15 growth hormone releasing hormone Homo sapiens 17-21 10199767-1 1999 The aim of the present study was to correlate the degree of the GH response to the combined arginine and GHRH (ARG+GHRH) test with clinical status in 157 adult hypopituitary patients and 35 healthy controls. Arginine 111-114 growth hormone releasing hormone Homo sapiens 105-109 10199767-13 1999 In conclusion, the results of the present study indicate that the degree of the GH response to ARG+GHRH is correlated with the severity of lipid profile abnormalities and substantiate the reliability of the ARG+GHRH test for the diagnosis of GHD in adults. Arginine 95-98 growth hormone releasing hormone Homo sapiens 211-215 10199767-13 1999 In conclusion, the results of the present study indicate that the degree of the GH response to ARG+GHRH is correlated with the severity of lipid profile abnormalities and substantiate the reliability of the ARG+GHRH test for the diagnosis of GHD in adults. Arginine 207-210 growth hormone releasing hormone Homo sapiens 99-103 10083901-4 1998 In fact, when combined with arginine or pyridostigmine, growth hormone-releasing hormone (GHRH) becomes one of the most potent and reproducible tests for distinguishing patients with severe GHD from normal subjects. Arginine 28-36 growth hormone releasing hormone Homo sapiens 90-94 10083901-5 1998 Owing to its tolerability and its suitability for use in the elderly, the GHRH + arginine test is the best alternative choice and is at least as sensitive as the ITT provided that appropriate cut-off limits are given. Arginine 81-89 growth hormone releasing hormone Homo sapiens 74-78 9589665-3 1998 GHRH + arginine (GHRH + ARG) is one of the most promising tests in alternative to ITT. Arginine 24-27 growth hormone releasing hormone Homo sapiens 0-4 11081183-13 1998 On the other hand, in E ARG restored the GH response to GHRH (1858.9 +/- 172.8 micrograms/L/h, p < 0.01) and even those to HEX (2069.5 +/- 528.7 micrograms/L/h, p < 0.01) and HEX + GHRH (4406.0 +/- 1079.2 micrograms/L/h, p < 0.05). Arginine 24-27 growth hormone releasing hormone Homo sapiens 56-60 11081183-13 1998 On the other hand, in E ARG restored the GH response to GHRH (1858.9 +/- 172.8 micrograms/L/h, p < 0.01) and even those to HEX (2069.5 +/- 528.7 micrograms/L/h, p < 0.01) and HEX + GHRH (4406.0 +/- 1079.2 micrograms/L/h, p < 0.05). Arginine 24-27 growth hormone releasing hormone Homo sapiens 187-191 9524798-11 1998 The GHRH-induced GH rise was also potentiated by ARG in both DS (2,243 +/- 362.4 micrograms/h; p < 0.001 vs. GHRH alone) and NS (2,764.3 +/- 325.7 micrograms/l/h; p < 0.005 vs. GHRH alone). Arginine 49-52 growth hormone releasing hormone Homo sapiens 4-8 9557822-10 1998 Arginine infusion restores the response of GH to GHRH, in both post-menopausal and obese subjects. Arginine 0-8 growth hormone releasing hormone Homo sapiens 49-53 10993592-7 1998 The potentiating effect of arginine on the GHRH-induced GH response is fully preserved while the stimulatory effect of GHRH + pyridostigmine is reduced in ageing. Arginine 27-35 growth hormone releasing hormone Homo sapiens 43-47 11081183-11 1998 ARG strikingly potentiated the GHRH-induced GH rise (2640.8 +/- 273.6 micrograms/L/h, p < 0.01) but not the HEX-induced one (2371.7 +/- 387.2 micrograms/L/h) as well as the synergistical effect of HEX and GHRH (4009.1 +/- 360.8 micrograms/L/h). Arginine 0-3 growth hormone releasing hormone Homo sapiens 31-35 11081183-11 1998 ARG strikingly potentiated the GHRH-induced GH rise (2640.8 +/- 273.6 micrograms/L/h, p < 0.01) but not the HEX-induced one (2371.7 +/- 387.2 micrograms/L/h) as well as the synergistical effect of HEX and GHRH (4009.1 +/- 360.8 micrograms/L/h). Arginine 0-3 growth hormone releasing hormone Homo sapiens 208-212 9438917-8 1997 In HPRL the GH response to GHRH (894.7 +/- 242.4 micrograms 90 min/l) was lower (p < 0.03) than that to HEX (1586.5 +/- 251.3 micrograms 90 min/l) and both were lower (p < 0.03) than that to GHRH + ARG (4468.8 +/- 941.7 micrograms 90 min/l). Arginine 204-207 growth hormone releasing hormone Homo sapiens 27-31 8793891-8 1996 ARG clearly increased the GH response to GHRH in the controls, whereas it was unable to further potentiate the GH-releasing effect of GHRH in runners, thus suggesting that the increased GH responsiveness to GHRH might be due to an exercise-related decrease in endogenous hypothalamic somatostatinergic activity. Arginine 0-3 growth hormone releasing hormone Homo sapiens 41-45 9302373-14 1997 In group B, ARG (0.2 g/kg) increased basal GH levels (16.2 +/- 5.2 vs 2.4 +/- 0.6 mU/I; P < 0.03) and potentiated the GH response to GHRH (119.6 +/- 20.4 vs 48.8 +/- 14.2 mU/I; P < 0.01). Arginine 12-15 growth hormone releasing hormone Homo sapiens 136-140 9302373-15 1997 In group C, ARG (0.5 g/kg) induced a clear GH rise (28.0 +/- 3.8 vs 2.0 +/- 0.6 mU/I; P < 0.001) and potentiated the GH response to GHRH (93.4 +/- 10.0 vs 34.2 +/- 4.6 mU/I; P < 0.001). Arginine 12-15 growth hormone releasing hormone Homo sapiens 135-139 9004172-0 1996 GH secretion in Prader-Labhard-Willi syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine. Arginine 97-105 growth hormone releasing hormone Homo sapiens 77-81 9004172-2 1996 In normal subjects, GH response to GHRH is known to be greatly potentiated to the same extent by pyridostigmine (PD) or arginine (ARG) which probably act via inhibition of hypothalamic somatostatin release. Arginine 120-128 growth hormone releasing hormone Homo sapiens 35-39 9004172-2 1996 In normal subjects, GH response to GHRH is known to be greatly potentiated to the same extent by pyridostigmine (PD) or arginine (ARG) which probably act via inhibition of hypothalamic somatostatin release. Arginine 130-133 growth hormone releasing hormone Homo sapiens 35-39 9004172-6 1996 In NC, the GHRH-induced GH rise was potentiated to the same extent by PD or ARG. Arginine 76-79 growth hormone releasing hormone Homo sapiens 11-15 9004172-10 1996 In conclusion, our results demonstrate that in PLWS the low somatotrope responsiveness to GHRH is not enhanced by cholinergic potentiation while it is increased by arginine. Arginine 164-172 growth hormone releasing hormone Homo sapiens 90-94 9202399-10 1997 Thus, in culture medium with lower amounts of L-arginine, L-NMMA blocked the IFN-gamma-induced inhibition of GHRH-stimulated GH release at a lower dose. Arginine 46-56 growth hormone releasing hormone Homo sapiens 109-113 9178029-8 1997 We conclude that 1) the elevated IR-GHRH in the cord blood plasma originates from the fetus and may have a primary role in enhancing secretion of GH which promotes growth in early human life, and 2) the participations of GHRH in the mechanisms of GH secretion seen after administrations of L-dopa, L-arginine and somatostatin are different. Arginine 298-308 growth hormone releasing hormone Homo sapiens 36-40 9178029-8 1997 We conclude that 1) the elevated IR-GHRH in the cord blood plasma originates from the fetus and may have a primary role in enhancing secretion of GH which promotes growth in early human life, and 2) the participations of GHRH in the mechanisms of GH secretion seen after administrations of L-dopa, L-arginine and somatostatin are different. Arginine 298-308 growth hormone releasing hormone Homo sapiens 221-225 8980159-10 1996 Similarly in GHD, the GH response to the GHRH + ARG test showed a good inter- (1st vs 2nd session: 2.3 +/- 0.5 vs 2.2 +/- 0.6 microg/l) and intra-individual reproducibility (r = 0.70, p < 0.005). Arginine 48-51 growth hormone releasing hormone Homo sapiens 41-45 8690107-14 1996 Normalization in older women of the reduced GH response to GH-RH by arginine supports this hypothesis. Arginine 68-76 growth hormone releasing hormone Homo sapiens 59-64 8626871-10 1996 We could show that decreasing GH responses to repeated GHRH can be avoided by a combined stimulation with GHRH/Arg. Arginine 111-114 growth hormone releasing hormone Homo sapiens 55-59 8626871-11 1996 These findings suggest that the decreased GH response to a second GHRH bolus may be partly due to an elevated hypothalamic somatostatin secretion, which can be suppressed by Arg. Arginine 174-177 growth hormone releasing hormone Homo sapiens 66-70 8626871-12 1996 The lower GH response to GHRH-Arg stimulation after a previous GHRH bolus suggests, furthermore, that the readily available GH pool in the human pituitary may be limited. Arginine 30-33 growth hormone releasing hormone Homo sapiens 25-29 8626871-12 1996 The lower GH response to GHRH-Arg stimulation after a previous GHRH bolus suggests, furthermore, that the readily available GH pool in the human pituitary may be limited. Arginine 30-33 growth hormone releasing hormone Homo sapiens 63-67 8616534-1 1996 Pyridostigmine (PD), a muscarinic cholinergic agonist, and arginine (ARG) clearly increase the growth hormone (GH) response to growth hormone-releasing hormone (GHRH) in man. Arginine 59-67 growth hormone releasing hormone Homo sapiens 127-159 8616534-1 1996 Pyridostigmine (PD), a muscarinic cholinergic agonist, and arginine (ARG) clearly increase the growth hormone (GH) response to growth hormone-releasing hormone (GHRH) in man. Arginine 59-67 growth hormone releasing hormone Homo sapiens 161-165 8616534-1 1996 Pyridostigmine (PD), a muscarinic cholinergic agonist, and arginine (ARG) clearly increase the growth hormone (GH) response to growth hormone-releasing hormone (GHRH) in man. Arginine 69-72 growth hormone releasing hormone Homo sapiens 127-159 8616534-1 1996 Pyridostigmine (PD), a muscarinic cholinergic agonist, and arginine (ARG) clearly increase the growth hormone (GH) response to growth hormone-releasing hormone (GHRH) in man. Arginine 69-72 growth hormone releasing hormone Homo sapiens 161-165 8006330-0 1994 Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects. Arginine 57-65 growth hormone releasing hormone Homo sapiens 113-145 8736266-14 1995 ARG increased the GHRH-induced GH rise in both groups, but in OB the GH response to ARG+GHRH (1458.4 +/- 439.0 mU/l/h, P < 0.03 vs GHRH alone) remained lower (P < 0.0001) than in CS (6396.2 +/- 772.2 mU/l/h, P < 0.01 vs GHRH alone). Arginine 0-3 growth hormone releasing hormone Homo sapiens 18-22 8736266-14 1995 ARG increased the GHRH-induced GH rise in both groups, but in OB the GH response to ARG+GHRH (1458.4 +/- 439.0 mU/l/h, P < 0.03 vs GHRH alone) remained lower (P < 0.0001) than in CS (6396.2 +/- 772.2 mU/l/h, P < 0.01 vs GHRH alone). Arginine 0-3 growth hormone releasing hormone Homo sapiens 88-92 8736266-14 1995 ARG increased the GHRH-induced GH rise in both groups, but in OB the GH response to ARG+GHRH (1458.4 +/- 439.0 mU/l/h, P < 0.03 vs GHRH alone) remained lower (P < 0.0001) than in CS (6396.2 +/- 772.2 mU/l/h, P < 0.01 vs GHRH alone). Arginine 0-3 growth hormone releasing hormone Homo sapiens 88-92 8736266-14 1995 ARG increased the GHRH-induced GH rise in both groups, but in OB the GH response to ARG+GHRH (1458.4 +/- 439.0 mU/l/h, P < 0.03 vs GHRH alone) remained lower (P < 0.0001) than in CS (6396.2 +/- 772.2 mU/l/h, P < 0.01 vs GHRH alone). Arginine 0-3 growth hormone releasing hormone Homo sapiens 88-92 7581965-5 1995 As the GHRH-induced GH rise in children is potentiated by arginine (ARG), even when administered by oral route at low dose (4 g), we studied also the interaction of oral GHRP-6 and ARG administration. Arginine 68-71 growth hormone releasing hormone Homo sapiens 7-11 7581965-5 1995 As the GHRH-induced GH rise in children is potentiated by arginine (ARG), even when administered by oral route at low dose (4 g), we studied also the interaction of oral GHRP-6 and ARG administration. Arginine 181-184 growth hormone releasing hormone Homo sapiens 7-11 7880938-0 1994 Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. Arginine 0-8 growth hormone releasing hormone Homo sapiens 74-78 7581965-5 1995 As the GHRH-induced GH rise in children is potentiated by arginine (ARG), even when administered by oral route at low dose (4 g), we studied also the interaction of oral GHRP-6 and ARG administration. Arginine 58-66 growth hormone releasing hormone Homo sapiens 7-11 7735336-0 1995 Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing"s syndrome. Arginine 10-18 growth hormone releasing hormone Homo sapiens 45-49 7735336-13 1995 ARG enhanced the GHRH-induced GH release in CS (331.9 +/- 51.9 micrograms/L/h vs GHRH alone, P < 0.0001), OB (852.4 +/- 162.1 micrograms/L/h, P < 0.0001) and C (3362.6 +/- 386.0 micrograms/L/h, P < 0.0002). Arginine 0-3 growth hormone releasing hormone Homo sapiens 17-21 7735336-13 1995 ARG enhanced the GHRH-induced GH release in CS (331.9 +/- 51.9 micrograms/L/h vs GHRH alone, P < 0.0001), OB (852.4 +/- 162.1 micrograms/L/h, P < 0.0001) and C (3362.6 +/- 386.0 micrograms/L/h, P < 0.0002). Arginine 0-3 growth hormone releasing hormone Homo sapiens 81-85 7850007-4 1995 In group B (N = 6) the GH response to GHRH co-administered with iv ARG on day 1 (1614.2 +/- 146.2 micrograms.l-1.h-1) was higher (p < 0.05) than that of GHRH alone (group A) and persisted unchanged after 7 (1514.7 +/- 366.5 micrograms.l-1.h-1) and 15 days (1631.7 +/- 379.1 micrograms.l-1.h-1) of treatment. Arginine 67-70 growth hormone releasing hormone Homo sapiens 156-160 7850007-5 1995 In group C (N = 15) the GH response to GHRH co-administered with oral ARG on day 1 (950.6 +/- 219.4 micrograms.l-1.h-1) was higher (p < 0.03) than that of GHRH alone (group A) but lower (p < 0.05) than that to GHRH plus iv ARG (group B). Arginine 70-73 growth hormone releasing hormone Homo sapiens 158-162 7850007-5 1995 In group C (N = 15) the GH response to GHRH co-administered with oral ARG on day 1 (950.6 +/- 219.4 micrograms.l-1.h-1) was higher (p < 0.03) than that of GHRH alone (group A) but lower (p < 0.05) than that to GHRH plus iv ARG (group B). Arginine 70-73 growth hormone releasing hormone Homo sapiens 158-162 7850007-5 1995 In group C (N = 15) the GH response to GHRH co-administered with oral ARG on day 1 (950.6 +/- 219.4 micrograms.l-1.h-1) was higher (p < 0.03) than that of GHRH alone (group A) but lower (p < 0.05) than that to GHRH plus iv ARG (group B). Arginine 229-232 growth hormone releasing hormone Homo sapiens 39-43 7729789-12 1995 ARG determined a significant increase of GHRH-induced GH release in all groups (p < 0.01). Arginine 0-3 growth hormone releasing hormone Homo sapiens 41-45 8033372-0 1994 Interaction of salbutamol with pyridostigmine and arginine on both basal and GHRH-stimulated GH secretion in humans. Arginine 50-58 growth hormone releasing hormone Homo sapiens 77-81 8033372-9 1994 ARG enhanced the GHRH-induced GH rise (P < 0.01) but its effect was abolished (P < 0.02) by SAL pretreatment. Arginine 0-3 growth hormone releasing hormone Homo sapiens 17-21 8051337-2 1994 On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Arginine 42-50 growth hormone releasing hormone Homo sapiens 117-121 8051337-2 1994 On the other hand, it has been shown that arginine (ARG) totally restores the reduced somatotropic responsiveness to GHRH observed in aging. Arginine 52-55 growth hormone releasing hormone Homo sapiens 117-121 8006330-4 1994 ARG strikingly enhanced the GHRH-induced GH rise (peak, mean +/- SE: 41.5 +/- 4.4 vs 11.7 +/- 5.3 micrograms/L, p < 0.05). Arginine 0-3 growth hormone releasing hormone Homo sapiens 28-32 8006330-6 1994 and 8 g oral ARG enhanced the GH response to GHRH (20.9 +/- 4.7 vs 8.3 +/- 2.8 micrograms/L, p < 0.03 and 31.0 +/- 5.3 vs 11.4 +/- 3.4 micrograms/L, p < 0.03, respectively). Arginine 13-16 growth hormone releasing hormone Homo sapiens 45-49 8241653-0 1993 Oral administration of arginine enhances the growth hormone response to growth hormone releasing hormone in short children. Arginine 23-31 growth hormone releasing hormone Homo sapiens 72-104 8121306-6 1994 These results confirm the strong inhibitory effect of FFAs on GH secretion, showing that they are even able to inhibit the potentiating effect of ARG on the GH response to GHRH. Arginine 146-149 growth hormone releasing hormone Homo sapiens 172-176 8103770-5 1993 In the second group of 12 hypothyroid patients, arginine infusion (30 g, iv, from 0-30 min) markedly increased the GH responses induced by GHRH administration (1 microgram/kg, iv, at 0 min; peak GH levels for arginine plus GHRH vs. placebo plus GHRH, 30.6 +/- 4.7 vs. 5.3 +/- 1.0 micrograms/L; P < 0.001). Arginine 48-56 growth hormone releasing hormone Homo sapiens 139-143 8121306-4 1994 GHRH-induced GH secretion was potentiated by ARG (2,009.9 +/- 463.2 v 922.0 +/- 244.4 micrograms/L/h, P < .05) and suppressed by lipid-heparin infusion (106.2 +/- 28.3 v 922.0 +/- 244.4 micrograms/L/h, P < .01). Arginine 45-48 growth hormone releasing hormone Homo sapiens 0-4 8121306-5 1994 Moreover, the lipid-heparin infusion inhibited the potentiating effect of ARG on the GHRH-induced GH increase (527.9 +/- 113.6 v 2,009.9 +/- 463.2 micrograms/L/h, P < .01). Arginine 74-77 growth hormone releasing hormone Homo sapiens 85-89 8103770-5 1993 In the second group of 12 hypothyroid patients, arginine infusion (30 g, iv, from 0-30 min) markedly increased the GH responses induced by GHRH administration (1 microgram/kg, iv, at 0 min; peak GH levels for arginine plus GHRH vs. placebo plus GHRH, 30.6 +/- 4.7 vs. 5.3 +/- 1.0 micrograms/L; P < 0.001). Arginine 48-56 growth hormone releasing hormone Homo sapiens 223-227 8103770-5 1993 In the second group of 12 hypothyroid patients, arginine infusion (30 g, iv, from 0-30 min) markedly increased the GH responses induced by GHRH administration (1 microgram/kg, iv, at 0 min; peak GH levels for arginine plus GHRH vs. placebo plus GHRH, 30.6 +/- 4.7 vs. 5.3 +/- 1.0 micrograms/L; P < 0.001). Arginine 48-56 growth hormone releasing hormone Homo sapiens 223-227 1592874-0 1992 Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. Arginine 0-8 growth hormone releasing hormone Homo sapiens 56-76 8227981-1 1993 Aim of this study was to verify whether arginine (ARG), which likely inhibits hypothalamic somatostatin release, has an enhancing effect on the GHRH-induced GH rise, even when administered orally at low dose. Arginine 40-48 growth hormone releasing hormone Homo sapiens 144-148 8227981-1 1993 Aim of this study was to verify whether arginine (ARG), which likely inhibits hypothalamic somatostatin release, has an enhancing effect on the GHRH-induced GH rise, even when administered orally at low dose. Arginine 50-53 growth hormone releasing hormone Homo sapiens 144-148 8227981-5 1993 Oral ARG-H (Group A, n = 11) induced a significant increase of basal GH levels (4.2 +/- 1.3 vs 1.0 +/- 0.4 micrograms/L, p < 0.02) and enhanced the GH response to GHRH (41.1 +/- 8.6 vs 25.3 +/- 6.7 micrograms/L, p < 0.02). Arginine 5-8 growth hormone releasing hormone Homo sapiens 166-170 8344645-4 1993 Before treatment the GH response to GHRH (AUC: 231.9 +/- 106.4 micrograms/l/h) was potentiated (p < 0.001) by ARG (932.6 +/- 166.2 micrograms/l/h). Arginine 113-116 growth hormone releasing hormone Homo sapiens 36-40 1479149-7 1992 Also ARG coadministration potentiated the GHRH-induced GH release in both groups (p < 0.0001) but in this case the elderly"s responses overlapped with the young"s. Arginine 5-8 growth hormone releasing hormone Homo sapiens 42-46 1355580-0 1992 Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man. Arginine 0-8 growth hormone releasing hormone Homo sapiens 86-118 1355580-2 1992 The aim of our study was to verify whether arginine ([Arg] 30 g intravenously [IV] in 30 minutes), a well-known GH secretagogue likely acting via inhibition of hypothalamic somatostatin release, counteracts the inhibitory effect of oral glucose (OG) administration (100 mg orally) on the GH response to GHRH (1 micrograms/kg IV bolus) in seven normal subjects (aged 20 to 30 years). Arginine 43-51 growth hormone releasing hormone Homo sapiens 303-307 1355580-2 1992 The aim of our study was to verify whether arginine ([Arg] 30 g intravenously [IV] in 30 minutes), a well-known GH secretagogue likely acting via inhibition of hypothalamic somatostatin release, counteracts the inhibitory effect of oral glucose (OG) administration (100 mg orally) on the GH response to GHRH (1 micrograms/kg IV bolus) in seven normal subjects (aged 20 to 30 years). Arginine 54-57 growth hormone releasing hormone Homo sapiens 303-307 1355580-3 1992 The GH response to GHRH (peak, 11.6 +/- 1.8 micrograms/L) was inhibited by previous OG load (peak, 7.4 +/- 0.8 micrograms/L; P less than .02 v GHRH alone) and potentiated by Arg coadministration (peak, 36.2 +/- 8.8 micrograms/L; P less than .03 v GHRH alone). Arginine 174-177 growth hormone releasing hormone Homo sapiens 19-23 1355580-4 1992 The potentiating effect of Arg on the GHRH-induced GH increase was unaffected by previous OG load (peak, 30.4 +/- 6.9 micrograms/L). Arginine 27-30 growth hormone releasing hormone Homo sapiens 38-42 1355580-5 1992 In conclusion, our results show that Arg abolishes the inhibitory effect of OG administration on the GHRH-induced GH response in man. Arginine 37-40 growth hormone releasing hormone Homo sapiens 101-105 8316397-0 1993 Comparison of the potentiating effect of pyridostigmine, arginine and propranolol on the GHRH-induced GH release in short children. Arginine 57-65 growth hormone releasing hormone Homo sapiens 89-93 8316397-2 1993 Pyridostigmine and arginine induced a similar potentiating effect on GHRH-induced GH rise (Peak, mean +/- SEM: 56.9 +/- 12.8 and 48.6 +/- 8.5 micrograms/L, respectively vs 12.3 +/- 1.6 micrograms/L; p < 0.05). Arginine 19-27 growth hormone releasing hormone Homo sapiens 69-73 8316397-5 1993 Our results confirm that pyridostigmine and arginine have a striking potentiating effect on the GHRH-induced GH rise in children and show that the tests with GHRH + PD and GH + H + ARG are ore reliable than that with GHRH + PROP to explore the secretory capacity of somatotroph cells. Arginine 44-52 growth hormone releasing hormone Homo sapiens 96-100 8316397-5 1993 Our results confirm that pyridostigmine and arginine have a striking potentiating effect on the GHRH-induced GH rise in children and show that the tests with GHRH + PD and GH + H + ARG are ore reliable than that with GHRH + PROP to explore the secretory capacity of somatotroph cells. Arginine 181-184 growth hormone releasing hormone Homo sapiens 96-100 1617799-0 1992 Differential effects of arginine on growth hormone releasing hormone and insulin induced growth hormone secretion. Arginine 24-32 growth hormone releasing hormone Homo sapiens 36-68 1617799-5 1992 RESULTS: Arginine increased GH responses to GHRH and decreased GH responses to hypoglycaemia, but this inhibitory effect of arginine was reversed by GHRH. Arginine 9-17 growth hormone releasing hormone Homo sapiens 44-48 1617799-5 1992 RESULTS: Arginine increased GH responses to GHRH and decreased GH responses to hypoglycaemia, but this inhibitory effect of arginine was reversed by GHRH. Arginine 124-132 growth hormone releasing hormone Homo sapiens 149-153 1588839-2 1992 Arginine (ARG) has been demonstrated to potentiate the GHRH-induced GH increase in normal subjects, likely acting via inhibition of hypothalamic somatostatin release. Arginine 0-8 growth hormone releasing hormone Homo sapiens 55-59 1588839-2 1992 Arginine (ARG) has been demonstrated to potentiate the GHRH-induced GH increase in normal subjects, likely acting via inhibition of hypothalamic somatostatin release. Arginine 10-13 growth hormone releasing hormone Homo sapiens 55-59 1588839-3 1992 To shed further light onto the mechanisms underlying the blunted GH secretion in obesity, we studied the effect of ARG (0.5 g/kg infused intravenously [IV] over 30 minutes) on both basal and GHRH (1 micron/kg IV)-stimulated GH secretion. Arginine 115-118 growth hormone releasing hormone Homo sapiens 191-195 1588839-6 1992 ARG potentiated the GH response to GHRH in obese patients (P less than .0003). Arginine 0-3 growth hormone releasing hormone Homo sapiens 35-39 1588839-7 1992 However, in these patients, the GH secretion elicited by GHRH, even when coadministered with ARG, persisted at reduced levels (P less than .005) when compared with controls. Arginine 93-96 growth hormone releasing hormone Homo sapiens 57-61 1588839-9 1992 In conclusion, ARG enhances the blunted GHRH-induced GH increase in obese patients, but the GH responses to ARG alone and to ARG + GHRH persist at lower levels than in normals. Arginine 15-18 growth hormone releasing hormone Homo sapiens 40-44 1592874-2 1992 The aim of our study was to evaluate the effect of arginine, a secretagogue that increases GH secretion acting at the hypothalamic level, probably by decreasing somatostatin tone, on GH-releasing hormone (GHRH)-induced GH secretion in three male and five female adult patients with nonendocrine disease who were receiving daily immunosuppressive glucocorticoid therapy. Arginine 51-59 growth hormone releasing hormone Homo sapiens 183-203 1592874-2 1992 The aim of our study was to evaluate the effect of arginine, a secretagogue that increases GH secretion acting at the hypothalamic level, probably by decreasing somatostatin tone, on GH-releasing hormone (GHRH)-induced GH secretion in three male and five female adult patients with nonendocrine disease who were receiving daily immunosuppressive glucocorticoid therapy. Arginine 51-59 growth hormone releasing hormone Homo sapiens 205-209 1592874-4 1992 GHRH-induced GH secretion was evaluated after 30-min iv infusion of saline (100 mL) or arginine (30 g) in 100 mL saline. Arginine 87-95 growth hormone releasing hormone Homo sapiens 0-4 1592874-6 1992 The GH responses to GHRH increased (P less than 0.05) after pretreatment with arginine compared to saline pretreatment in both normal subjects (GH peak, 36.6 +/- 4.0 micrograms/L) and steroid-treated patients (GH peak, 28.4 +/- 5.5 micrograms/L). Arginine 78-86 growth hormone releasing hormone Homo sapiens 20-24 1592874-8 1992 Thus, arginine is able to normalize the GH response to GHRH in patients receiving chronic glucocorticoid treatment. Arginine 6-14 growth hormone releasing hormone Homo sapiens 55-59 1543013-0 1992 GH response to GHRH, insulin, clonidine and arginine after GHRH pretreatment in children. Arginine 44-52 growth hormone releasing hormone Homo sapiens 59-63 1543013-4 1992 Moreover, comparing the GH peak values following the second stimulus, it appears that the greatest GH responses were elicited by GHRH (1.31 +/- 0.23 nmol/l) and clonidine (1.11 +/- 0.22 nmol/l), while the lowest was elicited by arginine (0.43 +/- 0.04 nmol/l). Arginine 228-236 growth hormone releasing hormone Homo sapiens 129-133 1307747-3 1992 The aim of our study was to evaluate the effects of arginine on the GH-releasing hormone (GHRH)-stimulated GH secretion in patients with hyperthyroidism. Arginine 52-60 growth hormone releasing hormone Homo sapiens 68-88 2270318-7 1990 Coadministration of GHRH accentuated the stimulatory effect of arginine on GH secretion. Arginine 63-71 growth hormone releasing hormone Homo sapiens 20-24 1944815-0 1991 Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults. Arginine 0-8 growth hormone releasing hormone Homo sapiens 67-99 1944815-9 1991 In conclusion, our results show that arginine potentiates the GHRH-induced GH secretion preventing the lessening of somatotrope responsiveness to the neurohormone alone. Arginine 37-45 growth hormone releasing hormone Homo sapiens 62-66 2229304-6 1990 ARG potentiated GH responsiveness to GHRH in both elderly (1787.1 +/- 226.0 micrograms/L.h; P = 0.0001 vs. GHRH alone) and young subjects (2113.0 +/- 444.3 micrograms/L.h; P = 0.001 vs. GHRH alone). Arginine 0-3 growth hormone releasing hormone Homo sapiens 37-41 2229304-6 1990 ARG potentiated GH responsiveness to GHRH in both elderly (1787.1 +/- 226.0 micrograms/L.h; P = 0.0001 vs. GHRH alone) and young subjects (2113.0 +/- 444.3 micrograms/L.h; P = 0.001 vs. GHRH alone). Arginine 0-3 growth hormone releasing hormone Homo sapiens 107-111 2229304-6 1990 ARG potentiated GH responsiveness to GHRH in both elderly (1787.1 +/- 226.0 micrograms/L.h; P = 0.0001 vs. GHRH alone) and young subjects (2113.0 +/- 444.3 micrograms/L.h; P = 0.001 vs. GHRH alone). Arginine 0-3 growth hormone releasing hormone Homo sapiens 107-111 2229304-7 1990 The potentiating effect of ARG on the GHRH-induced GH response was greater in elderly than in young subjects (1013.0 +/- 553.5% vs. 237.9 +/- 79.1%; P = 0.0001); thus, the GH increase induced by combined administration of ARG and GHRH overlapped in two groups. Arginine 27-30 growth hormone releasing hormone Homo sapiens 38-42 2229304-7 1990 The potentiating effect of ARG on the GHRH-induced GH response was greater in elderly than in young subjects (1013.0 +/- 553.5% vs. 237.9 +/- 79.1%; P = 0.0001); thus, the GH increase induced by combined administration of ARG and GHRH overlapped in two groups. Arginine 27-30 growth hormone releasing hormone Homo sapiens 230-234 2229304-7 1990 The potentiating effect of ARG on the GHRH-induced GH response was greater in elderly than in young subjects (1013.0 +/- 553.5% vs. 237.9 +/- 79.1%; P = 0.0001); thus, the GH increase induced by combined administration of ARG and GHRH overlapped in two groups. Arginine 222-225 growth hormone releasing hormone Homo sapiens 38-42 1982090-2 1990 In 4 normal subjects, a bolus injection of 50 micrograms of GHRH followed by 0.5 g/kg Arg infusion after 90 min evoked two GH peaks and the priming of the GHRH potentiated Arg-induced GH peak by 88% of that by Arg alone. Arginine 86-89 growth hormone releasing hormone Homo sapiens 155-159 1982090-2 1990 In 4 normal subjects, a bolus injection of 50 micrograms of GHRH followed by 0.5 g/kg Arg infusion after 90 min evoked two GH peaks and the priming of the GHRH potentiated Arg-induced GH peak by 88% of that by Arg alone. Arginine 172-175 growth hormone releasing hormone Homo sapiens 60-64 1982090-2 1990 In 4 normal subjects, a bolus injection of 50 micrograms of GHRH followed by 0.5 g/kg Arg infusion after 90 min evoked two GH peaks and the priming of the GHRH potentiated Arg-induced GH peak by 88% of that by Arg alone. Arginine 172-175 growth hormone releasing hormone Homo sapiens 155-159 1982090-2 1990 In 4 normal subjects, a bolus injection of 50 micrograms of GHRH followed by 0.5 g/kg Arg infusion after 90 min evoked two GH peaks and the priming of the GHRH potentiated Arg-induced GH peak by 88% of that by Arg alone. Arginine 172-175 growth hormone releasing hormone Homo sapiens 60-64 1982090-2 1990 In 4 normal subjects, a bolus injection of 50 micrograms of GHRH followed by 0.5 g/kg Arg infusion after 90 min evoked two GH peaks and the priming of the GHRH potentiated Arg-induced GH peak by 88% of that by Arg alone. Arginine 172-175 growth hormone releasing hormone Homo sapiens 155-159 1974484-0 1990 Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Arginine 0-8 growth hormone releasing hormone Homo sapiens 25-29 1974484-8 1990 In conclusion, our results show that in children ARG administration potentiates GHRH- but not PD-induced GH increase. Arginine 49-52 growth hormone releasing hormone Homo sapiens 80-84 1974484-10 1990 Combined administration of either ARG or PD with GHRH has a similar striking GH-releasing effect which is clearly higher than that of GHRH alone. Arginine 34-37 growth hormone releasing hormone Homo sapiens 134-138 2549156-4 1989 A high variability was found both in the 24-h GH secretion expressed as area under the curve above the baseline (0-1588 mU/l x 24 h) and the maximal GH response to GHRH (5-296 mU/l), as well as after an arginine-insulin tolerance test (4-59 mU/l). Arginine 203-211 growth hormone releasing hormone Homo sapiens 164-168 1982090-3 1990 In contrast, Arg pretreatment suppressed the GHRH-induced GH peak to a level of 15%. Arginine 13-16 growth hormone releasing hormone Homo sapiens 45-49 1982090-8 1990 In 4 other normal subjects, the effect of endogenous GH fluctuation on the GHRH-Arg test was examined in the morning, afternoon and evening. Arginine 80-83 growth hormone releasing hormone Homo sapiens 75-79 1982090-11 1990 The GHRH-Arg test is therefore able to evaluate GH secretory dynamics through two major mechanisms, GHRH stimulation and SRIH inhibition in a single procedure, reducing the incidence of false negative GH response to Arg. Arginine 9-12 growth hormone releasing hormone Homo sapiens 4-8 1982090-11 1990 The GHRH-Arg test is therefore able to evaluate GH secretory dynamics through two major mechanisms, GHRH stimulation and SRIH inhibition in a single procedure, reducing the incidence of false negative GH response to Arg. Arginine 9-12 growth hormone releasing hormone Homo sapiens 100-104 1982090-11 1990 The GHRH-Arg test is therefore able to evaluate GH secretory dynamics through two major mechanisms, GHRH stimulation and SRIH inhibition in a single procedure, reducing the incidence of false negative GH response to Arg. Arginine 216-219 growth hormone releasing hormone Homo sapiens 4-8 32720093-2 2021 Most studies use the growth-hormone-releasing hormone plus arginine (GHRH-arginine) test. Arginine 59-67 growth hormone releasing hormone Homo sapiens 69-73 3145820-7 1988 Following GHRH pretreatment the GH response to arginine was enhanced, with peak values of 19.3 +/- 6.4 vs 53.3 +/- 16.5 mU/l (mean +/- SEM) respectively (P less than 0.02). Arginine 47-55 growth hormone releasing hormone Homo sapiens 10-14 3121486-1 1987 The effect of insulinhypoglycemia and arginine infusion on circulating concentrations of plasma growth hormone-releasing hormone (GHRH) and growth hormone (GH) has been studied in 24 children (4.4 to 14.3 years). Arginine 38-46 growth hormone releasing hormone Homo sapiens 96-128 3121486-1 1987 The effect of insulinhypoglycemia and arginine infusion on circulating concentrations of plasma growth hormone-releasing hormone (GHRH) and growth hormone (GH) has been studied in 24 children (4.4 to 14.3 years). Arginine 38-46 growth hormone releasing hormone Homo sapiens 130-134 3091296-5 1986 The GHRH data in these patients are in agreement with those in older literature on hGH responsiveness to stimuli such as L-dopa, arginine and insulin induced hypoglycaemia. Arginine 129-137 growth hormone releasing hormone Homo sapiens 4-8 30973645-13 2019 CONCLUSIONS: In a large group of previously GH-treated young adults with PWS, approximately 1 in 7 exhibited a GH peak <9 mug/L during a GHRH-arginine test. Arginine 145-153 growth hormone releasing hormone Homo sapiens 140-144 31116442-7 2019 The adolescents were re-examined after 3 months off rhGH using both IGF-1 and GHRH-arginine tests. Arginine 83-91 growth hormone releasing hormone Homo sapiens 78-82 31286103-9 2019 On follow-up, GH deficiency due to GHRH resistance was suspected and confirmed by clonidine and arginine stimulation tests. Arginine 96-104 growth hormone releasing hormone Homo sapiens 35-39 29982753-9 2018 GHRH and arginine stimulation performed almost similarly to the ITT; however, in one study GHRH with arginine stimulation had 66% sensitivity and 88% specificity compared with the ITT. Arginine 101-109 growth hormone releasing hormone Homo sapiens 91-95